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Introduction {#sec1}
============

Human pluripotent stem cells (hPSCs) and their differentiated derivatives offer the exciting opportunity to develop tools to study and treat human diseases. However, robust and reproducible control of hPSC fate remains challenging. Small molecules offer one approach to control hPSC fate, and the discovery and characterization of these compounds can be facilitated by cell-based phenotypic high-throughput screening (HTS). Emerging data from hPSC assays has revealed variable and contradictory observations, even with matched cell lines and protocols ([@bib11]). Although the factors underlying this variability are not completely known, population context has been identified as a main contributor to assay inconsistency ([@bib30]). Spatially heterogeneous ([@bib21]) micro-environmental factors such as endogenous ligands, extra-cellular matrix proteins (ECMPs), and cell subpopulations are strong regulators of hPSC fate. Specifically, spatial cell distribution has been shown to affect hPSC self-renewal ([@bib16]), differentiation trajectories in both normal and patient-derived cells ([@bib2], [@bib3]), and disease phenotypes ([@bib32]).

Consequently, robust assays that combine defined culture conditions with comprehensive analysis of cell responses to exogenous cues are needed. To this end, we developed a chemically defined cell patterning-based high-throughput (HTP) assay, engineering colony size, local cell density, medium composition, and substrate for rapid and robust measurement of hPSC fate responses to exogenous cues ([@bib18]). We applied the assay to screen a library of kinase inhibitors for effects on four early hPSC fates. For each compound, the change in yield and purity in the resulting pluripotent, neuroectoderm (NE), mesendoderm, and extra-embryonic populations were simultaneously tracked, allowing for estimation of selection and induction events. Our analysis identified mammalian target of rapamycin (mTOR) inhibitors, such as rapamycin, as having a strong mesendoderm-inducing effect on hPSCs. Rapamycin was subsequently shown to synergize with bone morphogenetic protein 4 (BMP4) and activin A to enhance BRACHYURY induction more than 3-fold, an effect that propagated to equivalent enhancements of hemogenic endothelium and blood progenitor cells. This study demonstrates the advantages of controlling micro-environmental parameters and measuring multiple subpopulation outputs in parallel on PSC fate screening assays. This strategy should enhance discovery in more complex and predictive multi-cell population drug-screening assays.

Results {#sec2}
=======

A Kinase Inhibitor Screen of hPSCs Revealed Lineage-Specific Regulators {#sec2.1}
-----------------------------------------------------------------------

We previously developed a 48-hr hPSC screen that employs control of spatial cell patterning to configure the hPSC micro-environment for rapid and robust response to exogenous cues (96μCP assay) ([@bib18]) ([Figure 1](#fig1){ref-type="fig"}A). Single-cell OCT4 and SOX2 costaining enables simultaneous classification of pluripotent (OCT4^+^SOX2^+^), NE (OCT4^−^SOX2^+^), mesendoderm (OCT4^+^SOX2^−^), and extra-embryonic/other (OCT4^−^SOX2^−^) cell fates. This platform can be used to screen test factor effects on yield (percentage) and purity (absolute number of cells) of each subpopulation per colony using in-house software ([Figure 1](#fig1){ref-type="fig"}B).

We applied this platform to screen a collection of 400 small-molecule kinase inhibitors at two concentrations (0.2 μM and 1 μM). To ensure a significantly large sample size, we performed further analysis only on compounds which yielded \>800 imaged cells per well, resulting in 707 unique conditions including five controls on each plate: base medium (blank), PSC supporting mouse embryonic fibroblast (MEF)-conditioned (CM), NE inducing transforming growth factor β (TGF-β) inhibitor and fibroblast growth factor 2 (FGF2) (TiF), mesendoderm inducing BMP4 with activin A (BA), and extra-embryonic inducing BMP4. The overall distributions of the compounds with respect to each subpopulation indicated that mesendoderm and extra-embryonic/other inducing compounds were underrepresented ([Figure 1](#fig1){ref-type="fig"}C). Control conditions showed high reproducibility across plates ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Calculation of the Z′ factor, a statistical parameter used to compare HTP assays ([@bib41]), for the pattern-based (Z′ = 0.94)and non-pattern-based ([@bib6]) (Z′ = 0.29, p \< 0.01) assays supported the rationale for controlling micro-environments to improve robustness ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C). Sample images of control conditions and select responders are shown in [Figure 1](#fig1){ref-type="fig"}D. Viability of endpoint cells was confirmed at 48 hr using calcein and Hoechst staining ([Figures 1](#fig1){ref-type="fig"}E and 1F).

To visualize factor effects on responding population cell yield and purity, we measured the percentage and average number of cells of each subpopulation per colony per well. For example, to visualize effects on the PSC population we subtracted the percentage and number of OCT4^+^SOX2^+^ cells obtained in the blank to obtain ΔOCT4^+^SOX2^+^ (%) and ΔOCT4^+^SOX2^+^ (number of cells per colony), respectively ([Figure 2](#fig2){ref-type="fig"}A). Based on the subpopulation positive controls, we set thresholds for yield and purity to obtain a list of "responders." Similar visualizations are shown for NE (OCT4^−^SOX2^+^) ([Figure 2](#fig2){ref-type="fig"}B) and mesendoderm (OCT4^+^SOX2^−^) ([Figure 2](#fig2){ref-type="fig"}C). Enlarged plots of the threshold regions showing compound names of responders are shown in [Figure S2](#mmc1){ref-type="supplementary-material"}. Visual inspection of responding compounds confirmed the expected yield and purity effects ([Figure 1](#fig1){ref-type="fig"}D). Based on these results, we sought to determine whether responding compounds were enriched for specific inhibitor targets.

Specific Kinase Inhibitor Targets for NE and Mesendoderm Induction Identified {#sec2.2}
-----------------------------------------------------------------------------

To identify fate-modulating pathways enriched in our library, we performed a hypergeometric test to obtain p values for the enrichment of each kinase target in the PSC, NE, and mesendoderm responder groups (five most enriched targets are shown in [Figures 2](#fig2){ref-type="fig"}D--2F; count of unique compounds for each kinase target is shown in [Figure S3](#mmc1){ref-type="supplementary-material"}A; count of kinase targets in responders and total screen is shown in [Table S1](#mmc1){ref-type="supplementary-material"}). For the PSC-enhanced cluster no target family was statistically enriched, indicating that the tested kinase inhibitors do not robustly rescue hPSCs from differentiation in the blank lacking exogenous FGF2 and activin A ([@bib36]). This suggests that, in contrast to differentiation, exogenous pathway agonists, or a combination of inhibitors, may be required to maintain pluripotency in vitro ([@bib33]). For NE responders we obtained the highest enrichment for small molecules targeting the ERK/MEK pathway (p = 2.9 × 10^−5^) ([Figure 2](#fig2){ref-type="fig"}E), as well as a high enrichment (p = 0.001) of small molecules targeting TGF-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Inhibition of TGF-β signaling has been well established to result in hPSC differentiation to NE ([@bib28], [@bib35]). We previously observed low levels of endogenous TGF-β signaling in the 96μCP assay, which likely contributes to lower than expected significance of ALK4/5/7 inhibitors. Lastly, in the mesendoderm responders we found the highest enrichment for mTOR inhibitors (p = 8.1 × 10^−11^) ([Figure 2](#fig2){ref-type="fig"}F).

In addition to target enrichment analysis, two-dimensional hierarchical clustering (707 conditions, eight outputs, 5,656 data points) revealed several distinct phenotype clusters ([Figure 2](#fig2){ref-type="fig"}G, left). A cluster of compounds that enhanced PSC (blue dendrogram) also contained the CM control ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Similarly, a cluster that enhanced NE (red dendrogram) also contained the TiF control ([Figure S3](#mmc1){ref-type="supplementary-material"}C). The few compounds that enhanced mesendoderm (purple dendrogram) clustered with two mesendoderm induction controls, BA and BA with FGF2 (BAF) ([Figure 2](#fig2){ref-type="fig"}G, right). In this cluster, 53% of the compounds targeted mTOR and no other kinase was targeted by more than one compound. Enrichment analysis of the three clusters revealed identically significantly enriched pathways as our threshold-based method ([Figure S3](#mmc1){ref-type="supplementary-material"}D), further confirming the ERK/MEK and mTOR enrichments found in the screen. Based on these results we sought to further validate the ERK/MEK and mTOR results.

ERK/MEK Inhibition Induces hPSC Differentiation to NE in a BMP-Dependent Manner {#sec2.3}
-------------------------------------------------------------------------------

Analyzing all the ERK/MEK inhibitors in our library, we observed a general increase in the percentage of NE cells at the expense of PSCs, with no changes in total cell number ([Figures 3](#fig3){ref-type="fig"}A and 3B). To further investigate the effect of MEK inhibition, we retested PD0325901 and found a significant reduction in PSC yield and increase in NE frequency (both p \< 0.001) ([Figure 3](#fig3){ref-type="fig"}C), but found no significant increase in NE cells per colony induced relative to the blank control (p = 0.43), indicative of selection ([Figure 3](#fig3){ref-type="fig"}D). Reports are mixed on the effects of MEK inhibition (via PD0325901) on neural induction, and there is strong evidence that variability in endogenous factors such as BMP has hindered interpretation of these previous results ([@bib10]).

To further investigate, we performed a meta-analysis of a previous dataset of the response of a panel of cell lines to a set of conditions including blank medium, PD0325901, and TiF, using the 96μCP assay ([@bib18]). This analysis demonstrated that PD0325901 and TiF variably induce early NE in a cell-line- and passage-dependent manner ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Next, to determine the dependencies of PD0325901-induced NE on other pathways, we compared the effect of PD0325901 on NE induction in the blank, with BA, or with 17 other single factors that are agonists or antagonists of major developmental pathways. When BMP4 was added with PD0325901, NE induction was reduced from 95% to less than 0.5% (p \< 0.002), confirming that NE is exceptionally sensitive to BMP4, strengthening the possibility that endogenous BMP4 abolishes NE induction ([Figure S4](#mmc1){ref-type="supplementary-material"}B). Notably, PD0325901 induction of NE was affected by other factors, including FGF2, activin A, TGF-β, insulin-like growth factor 1, and heregulin β1, congruent with previous proposals that inhibition of MEK, BMP, and TGF-β signaling ([@bib10]) or dual BMP and TGF-β signaling ([@bib13]) may indeed robustly induce NE regardless of variations in endogenous signaling. Together, these data confirm that NE induction via MEK inhibition alone is highly variable across hPSC lines, support our hypothesis that this induction is sensitive to BMP inhibition, and demonstrate that our platform can reveal subtle molecular perturbations of PSC fate.

mTOR Inhibitors Dose-Dependently Induce Mesendoderm in hPSCs {#sec2.4}
------------------------------------------------------------

Our analysis indicated a strong effect of mTOR inhibition on mesendoderm induction. Conflicting reports show that mTOR inhibition inhibits PSCs and enhances serum-mediated differentiation toward mesoderm and endoderm ([@bib43]), or may enhance the purity of pluripotent cells ([@bib8]). To validate that mTOR inhibitors enhance mesendoderm induction, we screened nine mTOR inhibitors at both 1 μM and 0.1 μM, and screened eight inhibitors of additional pathways implicated in hPSC regulation. Ranking the compounds according to level of effect on mesendoderm induction (%OCT4^+^SOX2^−^), the mTOR inhibitors clearly separated from the others and the majority of conditions tested significantly enhanced the percentage of OCT4^+^SOX2^−^ cells relative to blank serum-free (SF) medium alone (p \< 0.05) ([Figure 4](#fig4){ref-type="fig"}A). Rapamycin at 1 μM was the strongest responder of all the conditions, comparable with the BA control. Rapamycin binds to FKBP12 and inhibits the kinase activity of mTOR complex 1 (mTORC1), which contains mTOR and RAPTOR ([@bib25]). A separate complex containing mTOR and RICTOR (mTORC2) is thought to be rapamycin insensitive, although this is cell-line and context dependent ([@bib14]). In contrast to rapamycin and its derivatives such as temsirolimus and everolimus, which only target mTORC1, next-generation dual mTORC1/2 inhibitors have been developed, such as AZD-8055 and KU-63794. Notably, within the 18 mTOR inhibitor treatments (nine compounds at two concentrations), the top half of ranked responders are enriched for compounds only targeting mTORC1 (p \< 0.005).

To further validate the effect of mTOR inhibitors on hPSCs, we performed ten-point dose curves of two mTOR inhibitors, rapamycin and AZD-8055, and again measured the four early OCT4/SOX2 subpopulations. As expected, both compounds increased the percentage of mesendoderm cells in a dose-dependent manner ([Figure 4](#fig4){ref-type="fig"}B). Surprisingly, a bimodal response to rapamycin was observed in the PSC response, where at 0.001 and 0.01 nM there was a moderate but significant enhancement of the percentage and number of PSCs. This enhancement was not seen at concentrations above 0.1 nM, where mesendoderm induction peaks at 0.1 μM ([Figure 4](#fig4){ref-type="fig"}C). The yield, and not just percentage, of PSCs are enhanced by low concentrations of rapamycin ([Figure 4](#fig4){ref-type="fig"}D). This bimodal response was seen with two additional replicates of rapamycin (not shown) but was not seen with AZD-8055, which may indicate that the mechanism is via mTORC1 inhibition ([Figure 4](#fig4){ref-type="fig"}D). Additional studies are required to understand this effect more completely.

mTOR Inhibitor-Mediated Induction of Mesendoderm Is BMP-Receptor and TGF-β-Receptor Dependent {#sec2.5}
---------------------------------------------------------------------------------------------

To gain insight into the mechanism behind mTOR inhibition inducing mesendoderm in hPSCs, we screened 14 agonists and antagonists of early development signaling pathways, alone and with rapamycin ([Figures 4](#fig4){ref-type="fig"}E and [S5](#mmc1){ref-type="supplementary-material"}). TGF-β1 and FGF2 moderately enhanced rapamycin-induced mesendoderm. Inhibition of either phosphatidylinositol-3-kinase (using LY-294002), a downstream effector of mTOR implicated in mesendoderm differentiation ([@bib27]), or Wnt (using IWP4) did not significantly alter the effect of rapamycin. The effects of rapamycin were abolished by the BMP type I receptor (ALK2/3) inhibitor LDN-193189, MEK inhibitor PD-032591, and TGF-β receptor (ALK4/5/7) inhibitor SB-431542. Consistent with our results, MEK inhibition has been shown to divert differentiation from mesendoderm ([@bib39]), indicating that mTOR inhibition is insufficient to overcome this effect. The LDN-193189 and SB-431542 results imply that rapamycin\'s effect on mesendoderm is dependent on BMP and TGF-β receptor-mediated signaling, which are both required for hPSC differentiation toward mesendoderm ([@bib37]). Addition of either (or both) of these inhibitors to rapamycin, relative to rapamycin alone, results in loss of the OCT4^+^SOX2^−^ population, no difference in the OCT4^+^SOX2^+^ population, and a moderately enhanced SOX2^+^OCT4^−^ population ([Figure S5](#mmc1){ref-type="supplementary-material"}A), with no change in the total number of cells per colony ([Figure S5](#mmc1){ref-type="supplementary-material"}B).

Based on the blocking effects of SB-431542 and LDN-193189, we reasoned that rapamycin, which induces mesendoderm alone in SF-defined medium, may act additively or synergistically with endogenous TGF-β/BMP signaling. We therefore generated a rapamycin dose curve with (rap+BA) and without (rap+BA) exogenous BMP4 (10 ng ml^−1^) and activin A (100 ng ml^−1^), and analyzed mesendoderm induction by BRACHYURY ([@bib42]) expression. The percentage and number of BRACHYURY^+^ cells in both rap+BA and rap+BA increased in a rapamycin dose-dependent manner. The maximum percentage of BRACHYURY^+^ cells achieved with rapamycin alone (19%) was comparable with the percentage achieved with BA alone (18%); however, rap+BA resulted in a more than 3-fold increased yield of BRACHYURY^+^ (57%) compared with BA alone (p \< 0.005) ([Figure 4](#fig4){ref-type="fig"}F). The number of BRACHYURY^+^ cells per colony was also enhanced in rap+BA relative to BA alone by 3.8-fold (p \< 0.005) ([Figure 4](#fig4){ref-type="fig"}G). Sample images are shown in [Figure 4](#fig4){ref-type="fig"}H. Similar trends were observed in dose curves generated from non-patterned hPSCs with rapamycin, or an alternative mTOR inhibitor (temsirolimus) and a BA background ([Figures S5](#mmc1){ref-type="supplementary-material"}C--S5F).

Knockdown of RAPTOR Phenocopies the Mesendoderm-Inducing Effects of Rapamycin {#sec2.6}
-----------------------------------------------------------------------------

Functionally, mTOR operates as part of two protein complexes, mTORC1 and mTORC2 (reviewed in [@bib24]), which are differentially regulated by upstream signals and have different downstream effectors. Although rapamycin was long thought to inhibit mTORC1, recent studies revealed that rapamycin can also inhibit mTORC2 in a cell-type-dependent manner ([@bib14]). To examine the role of each mTOR complex in rapamycin-induced mesendoderm differentiation, we targeted RAPTOR (mTORC1 specific) and RICTOR (mTORC2 specific) with small interfering RNA (siRNA). PSCs were seeded in pluripotency medium with siRNA against either RAPTOR (siRAPTOR) or RICTOR (siRICTOR). Two days after seeding, the medium was exchanged with fresh medium under three conditions (+blank, +rapamycin, or +BA), in the presence of siRNA. Analysis of OCT4 and SOX2 expression was conducted at day 4 ([Figure 5](#fig5){ref-type="fig"}A). In blank medium, siRAPTOR enhanced the percentage of mesendoderm (OCT4^+^SOX2^−^) cells relative to control scrambled siRNA (siCTRL) (p \< 0.0005), but siRICTOR had no significant effect. Addition of both siRAPTOR and siRICTOR gave a phenotype similar to siRAPTOR alone, and gave rise to a significantly higher percentage of mesendoderm cells than siRICTOR alone (p \< 0.05). In the presence of rapamycin, siRAPTOR again had a significant effect (p \< 0.0005), and siRICTOR was not significantly different from siCTRL. This result indicates that rapamycin (at 0.1 μM) is not completely inhibiting mTORC1. In the presence of BA, siRAPTOR also enhances the percentage of OCT4^+^SOX2^−^ cells relative to siCTRL (p \< 0.0005). Interestingly, in this medium condition siRICTOR also enhanced the percentage of OCT4^+^SOX2^−^ (p \< 0.0005), indicating that the effect of mTORC2 inhibition is dependent on TGF-β/BMP signaling. Focusing on the BA conditions, we repeated the siRNA assay and stained for BRACHYURY. As expected, siRAPTOR significantly enhanced both percentage ([Figure 5](#fig5){ref-type="fig"}B) and number ([Figure 5](#fig5){ref-type="fig"}C) of BRACHYURY^+^ cells, similarly to rapamycin treatment. Sample images are shown in [Figure 5](#fig5){ref-type="fig"}D. No effect was observed from siRICTOR on BRACHYURY induction, indicating that the effect of rapamycin on BRACHYURY induction is primarily through mTORC1 and not mTORC2. These results also indicate a divergence between the OCT4^+^SOX2^−^ readout and BRACHYURY expression and further corroborate that rapamycin is acting via inhibition of mTOR signaling, not via non-specific effects.

mTOR Inhibition Impedes Endoderm and Enhances Mesoderm Differentiation {#sec2.7}
----------------------------------------------------------------------

Based on the observation that mTOR inhibition enhances the purity and number of mesendoderm cells, we investigated the effect of rapamycin on specific downstream mesoderm and endoderm progenitors. We first differentiated hPSCs, in either BA or rap+BA (0.1 μM) for 42 hr, and assessed various markers of NE (*PAX3*, *PAX6*), mesendoderm (*MIXL1*, *BRACHYURY*), mesoderm (*MEIS1*, *MYB*), cardiac precursor (*MESP1*, *NKX2.5*, *PDGFRa*), hematopoietic (*RUNX1*), definitive endoderm (*EOMES*), primitive endoderm (*GATA6*, *AFP*), and trophectoderm (*HAND1*) lineages via qRT-PCR ([Figure S6](#mmc1){ref-type="supplementary-material"}A). In general, rapamycin supplementation enhanced all differentiated lineage markers, with the exception of *HAND1*, a marker of trophectoderm, and *EOMES*, associated with definitive endoderm (DE).

We next specifically tested the effect of rapamycin on DE induction. Differentiation to DE is a multi-step process including a 1-day induction phase (D0) where cells are exposed to activin A (100 ng ml^−1^) and the glycogen synthase kinase 3β (GSK3β) inhibitor CHIR99021 (CHIR, 2 μM) ([@bib23]). We tested various concentrations of rapamycin at D0 and measured the resulting FOXA2^+^SOX17^+^ DE at day 5. Although DE differentiation protocols can be extremely efficient in specific cell lines ([@bib19]), differentiation efficacy is known to vary greatly between different cell lines ([@bib18]). Thus we tested four cell lines with varying DE induction efficiencies and demonstrated that rapamycin dose-dependently reduced DE induction (%FOXA2^+^SOX17^+^ cells) in PDX1, HES2, and HES3-RUNX1-GFP cell lines, and had no effect on H9 DE induction ([Figure 6](#fig6){ref-type="fig"}A). These results show that rapamycin does not enhance endoderm differentiation and may be specific to mesoderm induction.

Next, to test the effect of mTOR inhibition on mesoderm-derived lineages, we evaluated hematopoietic differentiation of hPSCs. During embryogenesis, hematopoietic cells are derived from specialized endothelial cells called hemogenic endothelium (HE), isolated using vascular endothelial cadherin (VECAD) and CD34 expression ([@bib9]). To track HE induction in our studies, hPSC (HES3-RUNX1-GFP cell line) aggregates were cultured in chemically defined medium ([@bib22]) in the presence of rapamycin (0.1 μM) from day 0 to 2 and VECAD^+^CD34^+^ expression was assessed throughout an 8-day time course. Controls were cultured in the absence of rapamycin. The CD34^+^VECAD^+^ expression profile revealed that rapamycin addition from day 0 to day 2 enhances both purity and yield of HE ([Figures 6](#fig6){ref-type="fig"}B and 6C). Note that day-6 rapamycin-generated CD34^+^VECAD^+^ cells were also CD73^−^ and CD184^−^ ([Figures S6](#mmc1){ref-type="supplementary-material"}B and S6C), further confirming their HE phenotype ([@bib7]). The maximum CD34^+^VECAD^+^ percentage reached in controls was 10% ± 4%, falling within the range of previously reported results in the literature ([@bib7]), whereas in rapamycin 30% ± 11% purity was attained (p \< 0.05) ([Figure 6](#fig6){ref-type="fig"}D). Rapamycin addition also enhanced HE purity in the HES2 cell line ([Figure S6](#mmc1){ref-type="supplementary-material"}D), demonstrating that our observations are not limited to the HES3-RUNX1-GFP line. Moreover, rapamycin conditions exhibited a 4-fold increase in CD34^+^VECAD^+^ cells on day 6 and a 2.5-fold increase on day 8 (99% confidence intervals shown in [Figure 6](#fig6){ref-type="fig"}E). Furthermore, kinase insert domain receptor (KDR, also known as vascular endothelial growth factor receptor 2) expression, an early marker of all blood cells ([@bib26]), nearly doubled on day 4 in rapamycin ([Figure S6](#mmc1){ref-type="supplementary-material"}E). To functionally assess whether early rapamycin treatment enhances blood progenitor induction, we seeded cells from cultures initiated either in the presence or absence of rapamycin in methylcellulose colony-forming cell (CFC) assays ([@bib5]). A 1.7-fold increase (p \< 0.05) in the number of CFCs per 10^5^ cells was obtained in rapamycin-treated conditions (202 ± 42 CFCs \[mean ± SEM\]) compared with control conditions (117 ± 26 CFCs) ([Figures 6](#fig6){ref-type="fig"}F and [S6](#mmc1){ref-type="supplementary-material"}F). Additionally, gene expression analysis at days 0, 1, and 2 confirmed that rapamycin addition significantly increased the expression of *BRACHYURY* (p \< 0.002) and *MIXL1* (p \< 0.0002) ([Figure S6](#mmc1){ref-type="supplementary-material"}G). These results demonstrate that rapamycin treatment during days 0 to 2 of hematopoietic differentiation of hPSCs enhances the blood progenitor phenotype. A summary of our findings on the role of mTORC1 in hPSC lineage-fate decisions is presented in [Figure 6](#fig6){ref-type="fig"}G.

Discussion {#sec3}
==========

We have applied an engineered micro-environment based HTS platform to screen a kinase inhibitor library simultaneously for regulators of PSCs, NE, and mesendoderm. Small-molecule control of cell fate is attractive for scale-up purposes, and a focused library could be instrumental in elucidating endogenous regulators of hPSC fate decisions. In line with a previous screen ([@bib6]), we found no single compound able to maintain long-term pluripotency, indicating that exogenous pathway agonists or possibly combinations of small-molecule inhibitors may be required for hPSC maintenance. Our multi-lineage readout enabled the discovery of specific pathways endogenously activated in hPSCs amenable to small-molecule control of lineage-specific differentiation. Patterning enabled a more rapid (48 hr versus 7 days) assay and robust response than non-pattern-based screens ([@bib6]). Additionally, the short assay duration limits the number of emergent subpopulations, allowing simultaneous detection of these subpopulations to be tracked by OCT4 and SOX2 costaining. In conjunction with cell-number readouts, selection and induction events can be reasonably discriminated.

Our analysis revealed that mTOR inhibitors added alone to SF-defined medium can induce mesendoderm, and our follow-up studies confirmed that rapamycin enhances the formation of HE and blood progenitors. Ten-point dose curves revealed a bimodal effect where rapamycin at low concentrations mildly enhances the purity and number of OCT4^+^SOX2^+^ PSCs, and higher concentrations reduce the OCT4^+^SOX2^+^ population and enhance mesendoderm differentiation. These results reconcile two previous studies: in line with [@bib8] we observe no negative effect on pluripotency of rapamycin at low concentrations, and in line with [@bib43] we observe loss of pluripotency and induction of mesendoderm at higher concentrations. In contrast to Zhou et al., we found that rapamycin strongly inhibits DE induction. This difference may be serum mediated or cell-line dependent. Additionally, emerging evidence suggests that separate induction mechanisms may confer distinct mesoderm/endoderm subtype potentials ([@bib17]).

Although both GSK3β and mTOR inhibition appear to enhance mesendoderm, rapamycin-treated hPSCs appear to generate significantly higher frequencies of CD34^+^VECAD^+^CD73^−^ HE phenotype cells compared with CHIR99021 (GSK3β inhibitor)-treated conditions. GSK3β inhibition has been reported to direct hPSC differentiation to blood progenitor ([@bib31]) and cardiac cells ([@bib15]), supporting its role as a driver of lateral plate-derived tissues. Our results indicate that mTOR inhibition is an efficient driver of hPSC differentiation to blood progenitor competent mesoderm. Comparing the mesendoderm subtypes that emerge in GSK3β- and mTOR-inhibited differentiation conditions is an important future direction of our study.

The observation that subnanomolar concentrations of rapamycin have a moderate enhancing effect on pluripotency corresponds with findings of [@bib12] showing that rapamycin at 0.01 and 0.03 nM enhances mouse somatic cell reprogramming efficiency nearly 2-fold while concentrations of 0.05 nM or greater have no effect or reduce reprogramming efficiency. Autophagy regulates homeostasis of pluripotency-associated transcription factors including OCT4 in hPSCs, with autophagy inhibition increasing transcription factor levels yet leading to differentiation ([@bib4]). Accordingly, low levels of mTOR inhibition may inhibit autophagy and enhance OCT4 levels in hPSCs sufficiently to enhance pluripotency, with higher levels of mTOR inhibition increasing OCT4 levels beyond a threshold to initiate differentiation. Alternatively, given that differentiated cell types such as hPSC-derived extra-embryonic endoderm are known to inhibit pluripotency ([@bib21]), it may be that rapamycin selectively inhibits these cell types, leading to increased hPSC numbers. Another possibility is that the cell-fate effects of discrete mTOR inhibition levels may be directly mediated by differential SMAD activation, as mTORC1 inhibition activates SMAD1 and SMAD5 in human prostate cancer cells ([@bib38]), and mTORC2 inhibition can enhance SMAD2 and SMAD3 activity via regulation of the SMAD2/3-T220/T179 linker residue ([@bib40]). Understanding the complex interplay between discrete levels of mTOR signaling, autophagy, pluripotency transcription factor homeostasis, signaling pathway activation, and effects on cell-fate choice and subpopulation dynamics remains an important direction of future studies.

The methods we present here are applicable to systems with heterogeneous subpopulations and complex micro-environmental regulation, such as in vitro stem cell and cancer models, and can be applied iteratively. Changes in micro-environmental cues have been attributed to cell-fate transitions ([@bib1]), and heterogeneity in micro-environmental context (such as population size, local cell density, and relative cell position) can deterministically explain phenotypic variance ([@bib29]). Improved techniques to control the cellular micro-environment in conjunction with improved single-cell analytics will further develop our understanding of molecular cell-fate regulation.

Experimental Procedures {#sec4}
=======================

Cell Culture {#sec4.1}
------------

We obtained hESC lines H9 (WA09) and H7 (WA07) from the WiCell Research Institute, and HES3-RUNX1-GFP (HES3-derived RUNX1-GFP) from A. Elefanty (Monash University). All experiments were performed with H9 unless stated otherwise. These cell lines were cultured according to previously published methods ([@bib18]). All cell stocks tested negative for mycoplasma contamination. See [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for additional cell line information.

Micro-Patterning hPSCs onto 96-Well Plates and Application of Small Molecules or Controls {#sec4.2}
-----------------------------------------------------------------------------------------

We patterned hPSCs on Matrigel into standard 96-well plates as previously described ([@bib18]) (see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}). Dissociation of hPSCs was performed using TrypLE for 3 min. TrypLE was inactivated with medium containing 20% KO-serum replacement (Invitrogen). Cells were centrifuged and resuspended in NutriStem (NS; StemGent 001-0005) and 10 μM ROCK inhibitor Y-27632. Cells were seeded at 10^5^ cells per well (or as described in the text) into 96-well plates, coated with either patterned or non-patterned Matrigel, and incubated for 6 hr. Cells were then washed twice with PBS and incubated for 42 hr in fresh test medium (SF supplemented with growth factors or small molecules, or CM). SF medium consists of DMEM/F12, 1× non-essential amino acids, 50 U ml^−1^ penicillin, 50 μg ml^−1^ streptomycin, 10 μg ml^−1^ bovine transferrin, 0.1 mM β-mercaptoethanol (all Invitrogen), 2% fatty acid-free Cohn\'s fraction V BSA (Serologicals), 1× trace elements A, B, and C (Mediatech), 50 μg ml^−1^ ascorbic acid (Sigma), and 7 μg ml^−1^ recombinant human insulin. The 400-compound library was obtained from the Ontario Institute of Cancer Research (OICR) ([Tables S2](#mmc2){ref-type="supplementary-material"} and [S3](#mmc3){ref-type="supplementary-material"}). The following control conditions were included on each 96-well plate: blank (SF medium with no added factors), CM, B (100 ng ml^−1^ BMP4), BA (10 ng ml^−1^ BMP4 and 100 ng ml^−1^ activin A), and TiF (40 ng ml^−1^ FGF2 and 10 μM SB431542).

Immunocytochemistry and High-Content Image Analysis {#sec4.3}
---------------------------------------------------

Immunocytochemistry was performed as previously described ([@bib18]; see also [Supplemental Experimental Procedures)](#mmc1){ref-type="supplementary-material"}. Single-cell x-y-coordinate and protein-expression data were exported in tab-delimited text files and imported into in-house software, ContextExplorer (Joel E.E. Ostblom, E.J.P.N., and P.W.Z., unpublished data) for exploration of colony-level details. For figures, 16-bit TIFF images were obtained for each channel, identical contrast adjustment was performed on all controls, and channels were combined into pseudo-colored composite images.

96-Well siRNA Transfection {#sec4.4}
--------------------------

Human PSCs were first seeded into non-patterned MG-treated 96-well plates at 25,000 cells per well in NS, and incubated for 48 hr. For siRNA transfection, Lipofectamine RNAiMAX transfection reagent (Invitrogen) was used as per manufacturer\'s instructions, adapted for hPSCs and 96-well plates (see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}).

Viability Analysis {#sec4.5}
------------------

To assess viability, we modified the patterned hPSC assay as follows. Instead of fixing at 48 hr, calcein AM (Invitrogen) (1:1,000) and Hoechst 33342 (1:1,000) were added directly to the medium, incubated for 30 min, and then imaged.

Differentiation of hPSCs toward Blood Progenitors and Definitive Endoderm {#sec4.6}
-------------------------------------------------------------------------

For ultra-high-throughput production of size-specified cell aggregates, 400-μm diameter micro-well plates (commercially available as Aggrewells, STEMCELL Technologies) were manufactured in-house in 24-well plates ([@bib34]). For depletion of MEFs, hPSCs were dissociated with TrypLE and plated onto Geltrex (diluted 1:50) for 48 hr in NS. After 48 hr, TrypLE was added for 5 min and then quenched with 50% fetal bovine serum in DMEM/F12. The resulting single-cell suspension was seeded at 6 × 10^5^ cells per well of a micro-well plate (500 cells per aggregate) in the presence of Y-27632 (for 24 hr) at 1,500 rpm for 5 min. Aggregates were cultured in hypoxia for 8 days in base medium supplemented with cytokines BMP4 (40 ng ml^−1^, R&D Systems), vascular endothelial growth factor (VEGF) (50 ng ml^−1^, R&D), SCF (40 ng ml^−1^, R&D), basic FGF (5 ng ml^−1^, Peprotech), and rapamycin (0.1 μM, Sigma). Note that rapamycin is highly labile, and we recommend minimizing freeze-thaw cycles and titrating for maximum effect. The base medium consists of StemPro34 (Invitrogen), ascorbic acid (50 μg ml^−1^, Sigma), L-glutamine (1% v/v, Invitrogen), penicillin/streptomycin (1% v/v, Invitrogen), 1-monothioglycerol (4 × 10^−4^ M, Sigma), and transferrin (150 μg ml^−1^, Roche). On day 2, hPSC-derived cells were transferred to low-cluster six-well plates, in medium without rapamycin, and cultured for an additional 6 days shaken at 85 rpm (Orbi-Shaker XL, Benchmark Scientific). Endoderm induction to FOXA2^+^SOX17^+^ DE was performed as previously described ([@bib23]).

qRT-PCR {#sec4.7}
-------

qRT-PCR was performed as described previously ([@bib20]). In brief, RNA was isolated using the PureLink RNA Mini Kit (Ambion) and reverse transcribed with Superscript III (Life Technologies). PCR was performed on the QuantStudio 6 Flex (Life Technologies) using SYBR Master Mix (Roche) and primers provided by the Center for Commercialization of Regenerative Medicine. Gene NCBI-RefSeq accession numbers are provided in [Table S4](#mmc1){ref-type="supplementary-material"}.

CFC Assay {#sec4.8}
---------

A minimum of 1.5 × 10^5^ cells were seeded on day 8 in 35-mm Greiner dishes in methylcellulose-based MethoCult H4435 Enriched medium (STEMCELL). Samples were scored based on morphology 14 days after plating as described by technical manuals provided by STEMCELL.

Statistical Analysis {#sec4.9}
--------------------

Statistics were computed using one-way ANOVA, two-factor ANOVA, or linear regression as indicated. All statistics were computed in MATLAB using p values as indicated. N values are independent replicates, not technical replicates, except where noted. Enrichment analysis was performed using the hypergeometric distribution in Microsoft Excel. Z′ factor was used to assess assay quality ([@bib41]). Z′ is defined as Z′ = 1 − (3σ~positive~ + 3σ~negative~)/\|μ~positive~ − μ~negative~\|, where μ and σ are the mean and SD of the positive (CM-treated) and negative (BMP4-treated) control as labeled. Hierarchical clustering was performed with MeV (MultiExperiment Viewer, <http://www.tm4.org/>) using Euclidan distance as the similarity metric (centered) and centroid linkage as the clustering method. Exploratory analysis was performed with Microsoft Excel and Tableau (Tableau Software, [www.tableau.com](http://www.tableau.com){#intref0015}).
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![HTS of Small-Molecule Regulators of hPSC Pluripotency, Primitive Streak, NE, and Extra-embryonic/Other Cell-Fate Decisions\
(A) Assay design. hPSCs are micro-patterned on micro-contact printed 200-μm diameter extracellular matrix proteins (ECMP) circles in 96-well plates. Control or base medium with test compounds is added to each well. After 48 hr, imaging is performed and single-cell OCT4 and SOX2 expression levels are quantified.\
(B) Subpopulation purity and high yield are measured to determine inductive effects of compounds. Diagram demonstrates the changes in composition and purity of the "pink" cell population.\
(C) Compound distribution ranked by induction efficiency of pluripotency, NE, primitive streak, and extra-embryonic/other cell fates.\
(D) Sample composite colony images from controls and selected responders stained for DNA (DAPI, blue), OCT4 (green), and SOX2 (red). BMP4 is the OCT4^−^SOX2^−^ control, CM is the OCT4^+^SOX2^+^ control, FGF2 + SB431542 is the OCT4^−^SOX2^+^ control, and BMP4 + activin A is the OCT4^+^SOX2^−^ control. Colony outlined with dotted white line. Scale bar, 100 μm.\
(E) Calcein (viability) staining of unfixed cells at 48 hr treated with hit compounds. Non-viable control treated with methanol. Colonies are outlined with a dotted white line. Scale bar, 200 μm.\
(F) 67 putative hit compounds ranked by increasing viability. n = 3 independent biological replicates. Error bars indicate SD.\
See also [Figure S1](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![Pathway Enrichment Analysis\
(A) Increase in PSC purity (%OCT4^+^SOX2^+^) versus increase in yield (number of OCT4^+^SOX2^+^ cells per colony) obtained from 712 unique treatments. Values from blank were subtracted (graph origin represents base medium alone). Thresholds for purity and yield were used to classify "pluripotency responders." Arrow indicates a sample responding compound.\
(B and C) Similar analysis as in (A) to classify (B) NE and (C) mesendoderm responders. Dotted lines outline the regions classified as responders.\
(D) Enrichment in PSC responders (shown in [Figure 1](#fig1){ref-type="fig"}D). p Values were obtained for each target, using the hypergeometric distribution, and shown in −log base 10. Threshold corresponds to p = 0.001.\
(E and F) Similar analysis as in (D) for (E) NE and (F) mesendoderm responders.\
(G) Two-dimensional hierarchical clustering of subpopulation yield and purity data across treatments. Left: sample similarity tree, with samples clustered. Enhanced primitive streak cluster is in purple, PSC cluster in blue, and NE cluster in red. Right: detailed view of enhanced primitive streak cluster, indicating compound name, concentration, and reported kinase targets indicated in red.\
See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}; [Table S2](#mmc2){ref-type="supplementary-material"}.](gr2){#fig2}

![PSC and NE Subpopulation Screen Analysis\
(A) Subpopulation percentages from all screened MEK/ERK inhibitors, ranked by PSC percentage response.\
(B) Subpopulation cells per colony from all screened MEK/ERK inhibitors, ranked by PSC percentage response.\
(C) The MEK inhibitor PD-0325901 increases the percentage of early NE and decreases the percentage of PSCs. ^∗^p \< 0.001, significant difference from blank control; n ≥ 3 independent biological replicates.\
(D) MEK inhibitor PD-0325901 does not increase the number of early NE. ^∗^p \< 0.01, significant difference from blank control; n ≥ 3 independent biological replicates.\
Error bars indicate SD. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![mTOR Inhibitors in Defined Medium Upregulate Mesendoderm via TGF-β and BMP Pathways\
(A) Nine mTOR inhibitors in the OICR library were tested at 1 and 0.1 μM. Additional inhibitors of kinases implicated in early development but not targeting mTOR ("other inhibitors") were also tested. Small molecules were ranked by effect magnitude to separate mTOR inhibitors from others. ^∗^p \< 0.01, ^∗∗^p \< 0.001 compared with blank; n = 3 independent biological replicates.\
(B) Ten-point dose curves of mTOR inhibitors rapamycin and AZD-8055 show a dose-dependent increase of % mesendoderm. ^∗^p \< 0.05 compared with blank control; n = 3 independent biological replicates. Blank and BA response shown as reference lines.\
(C) Ten-point dose curves of rapamycin show a bimodal increase in % PSCs. ^∗^p \< 0.05 compared with blank (0 rapamycin); n = 3 independent biological replicates.\
(D) Ten-point dose curves of rapamycin and AZD-8055 effect on number of PSCs per colony at subnanomolar concentrations of rapamycin but not AZD-8055. ^∗^p \< 0.05 compared with blank (0 rapamycin); n = 3 independent biological replicates.\
(E) 14 factors (ligands and small molecules) targeting early development pathways tested alone and with rapamycin to screen for interactions. n = 3 independent biological replicates. ^∗^p \< 0.05, compared with blank + rapamycin condition.\
(F) Dose curves of rapamycin performed alone and with BMP4 (10 ng ml^−1^) and activin A (100 ng ml^−1^) showing average percentage of BRACHYURY^+^ cells per well was quantified. ^∗^p \< 0.05 and ^∗∗^p \< 0.005 both compared with the equivalent condition without rapamycin; n = 3 independent biological replicates. Response to blank and BMP4 and activin A alone ("BA") are shown as reference lines.\
(G) Same experiment as in (F) showing the number of BRACHYURY cells per colony. ^∗^p \< 0.05, ^∗∗^p \< 0.005 compared with the equivalent condition without rapamycin; n = 3 independent biological replicates.\
(H) Images of cells stained for DNA (DAPI, blue) and BRACHYURY expression (red), with treatments as indicated. Colony outlined with dotted white line. Scale bar, 200 μm.\
Error bars indicate SD. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![mTOR Inhibition Synergizes with BMP4 and Activin A in Inducing Mesendoderm\
(A) The effect of siRNA on OCT4^+^SOX2^−^ mesendoderm. siRNA was applied to non-patterned hPSCs in different medium conditions as noted. ^∗^p \< 0.05, ^∗∗∗^p \< 0.0005; n = 3 independent biological replicates.\
(B) The effect of siRNA on BRACHYURY expression. siRNA was applied in different medium conditions as noted to non-patterned hPSCs. ^∗^p \< 0.05; n = 4 independent biological replicates.\
(C) Same experiment as in (B), showing number of BRACHYURY^+^ cells per field and total cells. ^∗∗^p \< 0.005, ^∗∗∗^p \< 0.0005; n = 4 independent biological replicates.\
(D) Images of cells stained for DNA (DAPI, blue) and BRACHYURY expression (red), with treatments as indicated. Scale bar, 500 μm.\
Error bars indicate SD.](gr5){#fig5}

![mTOR Inhibition Enhances HE and Blood Induction\
(A) Four hPSC cell lines were differentiated to DE using a 5-day protocol and analyzed for FOXA2^+^SOX17^+^ expression. Rapamycin was added as indicated during the D0 phase. n = 3 independent biological replicates. Error bars indicate SD.\
(B) Representative flow cytometry scatterplots of VECAD and CD34 expression in day 8 hPSC-derived HE with (top) and without (bottom) rapamycin.\
(C) Time course showing VECAD^+^CD34^+^ cells from days 1--8 of differentiation showing percentage (top) and number per well (bottom) with and without rapamycin. N indicates number of independent biological replicates. Error bars indicate SD.\
(D) Comparison of the maximum VECAD^+^CD34^+^ percentage obtained with or without rapamycin. ^∗^p \< 0.05; n = 3 independent biological replicates. Error bars indicate SD.\
(E) Comparison of the fold increase in number of CD34^+^VECAD^+^ achieved with rapamycin relative to without rapamycin, on days 6 and 8. n = 3 independent biological replicates. Error bars indicate 99% confidence interval.\
(F) CFC comparison of definitive blood obtained with and without rapamycin. n = 3 independent runs of the HES2 (one replicate) and RUNX1-GFP (two replicates) cell lines. Error bars indicate SD. ^∗^p \< 0.05 (paired Student\'s t test).\
(G) Summary of the role of rapamycin in hPSCs.\
See also [Figure S6](#mmc1){ref-type="supplementary-material"}.](gr6){#fig6}
